- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
September 10, 2024Robins Kaplan Ranks Among Top Firms In 2024 American Lawyer Mid-Level Associates Survey
-
September 9, 2024Federal Judge Orders Transformative Reforms at West LA VA Campus in Major Victory for Disabled Veterans
-
September 9, 2024Robins Kaplan Partners Named to 2025 Lawdragon 500 Leading Litigators in America Guide
-
September 27, 2024Minnesota’s Largest Patent Jury Verdict: The Inside Story
-
October 9, 2024Perception vs. Reality in Trust and Estate Matters:
-
October 20, 2024License Agreement Disputes:
-
September 2024Q&A with Alan Harter, Founder of Pactolus Private Wealth Management
-
August 2024Recruiting & Retaining Diverse Attorneys: Building an Inclusive Legal Profession
-
August 22, 2024Prior Art Takeaways From Fed. Circ. Public Disclosure Ruling
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Allergan, Inc. v. Sandoz Inc.
An ANDA product having a pH range of 6.8-7.2 infringes, literally and under the doctrine of equivalents (amendments related only tangentially to pH), a claim term related to pH of “about 7.3;” and given the unpredictability of ophthalmic formulation, among other things, the patents in suit are not invalid.
Spring 2014
Case Name: Allergan, Inc. v. Sandoz Inc., Case No. 11-cv-441, Dkt. No. 136 (E.D. Tex. Jan. 13, 2014) (Schneider, J.)
Drug Product and Patent(s)-in-Suit: Lumigan® (bimatoprost); U.S. Patents Nos. 7,851,504 (“the ’504 patent”), 8,278,353 (“the ’353 patent”), 8,299,118 (“the ’118 patent”), 8,309,605 (“the ’605 patent”), and 8,339,479 (“the ’479 patent”)
Nature of the Case and Issue(s) Presented: Allergan asserted patent infringement claims against various defendants for attempting to make and market generic versions of Lumigan. Some defendants argued that their ANDA products would not infringe the patents in suit because those defendants stated in their ANDA that the product’s pH range during its shelf life is 6.8–7.2. The asserted claims of the ’502, ’497, and ’605 patents all require a pH of “about 7.3.”
Defendants also argued that the asserted claims were invalid as obvious in view of the prior art. Allergan, on the other hand, asserted that the prior art taught away from the claimed invention of using 0.01% bimatoprost with 200 ppm benzalkonium chloride. Finally, Allergan argued that that it was entitled to a permanent injunction because it would suffer irreparable harm if defendants were allowed to enter the market with their proposed ANDA products.
The court reached the following conclusions: (i) defendants’ proposed generic drug products infringed Allergan’s patents; (ii) Allergan’s patents are not invalid and are enforceable; and (iii) Allergan was entitled to a permanent injunction preventing defendants from introducing generic versions of Lumigan until the expiration of Allergan’s patents.
Why Allergan Prevailed: The asserted claims were not invalid, because the prior art did not teach the claimed invention. Ophthalmic formulation is a very unpredictable art. The referenced prior art did not suggest that there was a finite number of predictable solutions. Indeed, some of the asserted prior art taught away from the claimed invention. The court found considerable differences between the prior art and the claimed invention. The court further rejected defendants’ argument that it would have been obvious to one of skill to try the claimed invention because of the numerous possibilities available, skepticism in the prior art, and the unpredictability in the art.
Next, the court found that the defendants’ proposed ANDA products infringed the patents in suit. As for some of defendants’ arguments concerning the pH limitation, the court found that pH levels around 7.0 were infringing both literally and under the doctrine of equivalents. The court rejected defendants’ argument that prosecution history estoppel applied because the amendments made during prosecution only tangentially related to the pH limitation.
Finally, the court granted a permanent injunction in favor of Allergan because the irreparable harm to Allergan outweighed the competition in the market that will result should the proposed ANDA products enter the market. The court also reasoned that patent protection was a greater public interest than entry of generics into the market place.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.